Does Geisinger Health Plan Cover Prolia?

What Is Prolia and Why Does Coverage Classification Matter?

Prolia is denosumab, a fully human monoclonal antibody that inhibits RANK ligand, blocking osteoclast formation and reducing bone resorption. The FDA approved denosumab for postmenopausal osteoporosis in June 2010 [1]. A key phase 3 trial, FREEDOM (N=7,868), showed that three years of denosumab 60 mg every 6 months reduced vertebral fracture risk by 68%, hip fracture risk by 40%, and nonvertebral fracture risk by 20% compared with placebo [2]. Those are not abstract numbers: hip fractures carry a one-year mortality of roughly 20 to 30% in adults over age 65 [3].

Coverage classification is the first thing to confirm. Because a nurse or physician administers Prolia in a clinical setting, most health plans, including Geisinger, process the claim under the medical benefit rather than the prescription drug benefit. For Medicare Advantage members, that means Part B rules apply: Geisinger covers 80% of the Medicare-allowed amount after the Part B deductible ($257 in 2025), and the member pays the remaining 20% coinsurance. On commercial plans, the cost-sharing percentage varies by tier assignment in Geisinger's provider agreement.

This distinction matters because prior authorization pathways, appeals processes, and copay assistance programs each differ depending on which benefit bucket applies. Confirm your benefit bucket by calling the member services number on the back of your Geisinger ID card before the first injection is scheduled.

Geisinger Health Plan Formulary Status for Prolia

Prolia does not sit in the standard pharmacy formulary the way a pill does. It appears on Geisinger's specialty drug list and is subject to medical-benefit coverage policies rather than a simple tier lookup. Geisinger, like most regional Blue Cross affiliates and large managed care organizations, follows clinical criteria derived from the American Association of Clinical Endocrinologists (AACE) 2020 postmenopausal osteoporosis guidelines [4] and the National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) clinical practice guidance [5].

Geisinger's medical-policy teams typically require that at least one of the following conditions is met before approving Prolia:

1. A DXA scan demonstrating a T-score of -2.5 or lower at the lumbar spine, total hip, or femoral neck.
2. A prior low-trauma (fragility) fracture after age 50 regardless of T-score.
3. A 10-year FRAX probability of major osteoporotic fracture of 20% or higher, or hip fracture probability of 3% or higher, per the BHOF intervention threshold [5].
4. Documented intolerance, contraindication, or treatment failure with an oral bisphosphonate (alendronate, risedronate) used for at least 12 months.
5. Bone loss secondary to aromatase inhibitor therapy in breast cancer patients or androgen deprivation therapy (ADT) in prostate cancer patients, both of which carry separate FDA-approved indications [1].

The AACE 2020 guidelines describe denosumab as a "preferred agent" for patients at very high fracture risk, defined as a recent fracture (within 24 months), T-score below -3.0, or a FRAX 10-year major fracture risk above 30% [4]. Providing this language verbatim in a prior authorization letter can improve approval odds.

Step-by-Step Prior Authorization Process for Geisinger Members

Prior authorization (PA) for Prolia through Geisinger follows a predictable pathway, though exact form numbers change annually. Your prescribing clinician's office initiates the process.

Step 1. Gather clinical documentation. The office needs a current DXA report (dated within 24 months), FRAX score printout, list of prior osteoporosis treatments and durations, relevant fracture history including imaging, and the specific ICD-10 diagnosis code (M81.0 for age-related osteoporosis without fracture, M80.00 for age-related osteoporosis with fracture, or the relevant cancer-treatment-related code).

Step 2. Submit the PA request. Geisinger accepts PA submissions through its online provider portal or by fax. Include a letter of medical necessity citing the BHOF intervention threshold [5] and the FREEDOM trial fracture-reduction data [2].

Step 3. Await the initial determination. Federal rules under 42 CFR 422.568 require Medicare Advantage plans to issue standard PA decisions within 14 calendar days and expedited decisions within 72 hours when a physician certifies that the standard timeline could seriously jeopardize health [6].

Step 4. If approved, the authorization typically covers two injections (one full year) before re-authorization is required. Discontinuing denosumab without transitioning to a bisphosphonate carries a rebound fracture risk: a 2017 analysis published in Osteoporosis International found vertebral fracture rates rising to 7.1% within 12 months of stopping denosumab without follow-on therapy [7]. That clinical fact is worth documenting upfront so the plan understands ongoing treatment is a safety requirement, not a preference.

Step 5. If denied, you receive a written denial with the specific clinical reason. Keep that letter. The denial triggers your right to appeal.

What the Prior Authorization Letter of Medical Necessity Should Include

A strong letter of medical necessity does more than list a diagnosis. It connects the patient's clinical picture to published evidence and to the plan's own stated coverage criteria.

Effective letters cite the FREEDOM trial's 68% vertebral fracture reduction [2], the AACE 2020 recommendation of denosumab as preferred therapy for very-high-risk patients [4], and any prior bisphosphonate trial with documented inadequate response (defined by the BHOF as a fracture or continued bone loss of more than 5% annually despite therapy) [5]. The letter should also note that denosumab's mechanism, RANK-ligand inhibition, is distinct from bisphosphonates, making it clinically appropriate for patients with GI intolerance or renal impairment, since denosumab carries no renal dose-adjustment requirement and is not renally cleared [1].

The HealthRX clinical team uses the following documentation checklist when supporting a Geisinger PA for Prolia:

• DXA report with T-scores at all three sites (lumbar, total hip, femoral neck)
• FRAX calculation with BMI entered, dated within 12 months
• Prior bisphosphonate trial: drug name, dose, duration, reason for stopping
• Fracture history: date, site, mechanism (confirm low-trauma)
• Current serum creatinine and eGFR (to document renal safety benefit of denosumab over zoledronic acid if relevant)
• Prescriber attestation linking the clinical picture to AACE 2020 "very high risk" criteria [4]
• Patient's functional status and fall-risk assessment (Timed Up and Go test result if available)

Submitting all seven elements in a single organized packet reduces the likelihood of an administrative denial based on missing information.

Appealing a Geisinger Prolia Denial

Denials happen. A 2021 analysis of Medicare Advantage prior authorization data found that plans denied 6.0% of prior authorization requests, but 75% of those appealed were eventually approved [8]. Commercial plan data from KFF similarly shows that roughly 54% of in-network denied claims are overturned on internal appeal [9].

Geisinger's appeals ladder for Medicare Advantage members follows CMS guidelines [6]:

1. Level 1: Plan Redetermination. Submit within 60 days of the denial notice. Geisinger must respond within 60 days for standard appeals or 72 hours for expedited appeals. Include all new clinical documentation not submitted with the original PA.

2. Level 2: Qualified Independent Contractor (QIC) Review. If Geisinger upholds the denial, you escalate to an independent review organization contracted by CMS. QIC decisions are issued within 60 days for standard or 72 hours for expedited appeals.

3. Level 3: Office of Medicare Hearings and Appeals (OMHA). Available if the dollar amount at issue meets the threshold (currently $180 in 2025 for an individual claim). A hearing before an administrative law judge follows.

4. Level 4: Medicare Appeals Council.

5. Level 5: Federal District Court (if the amount at stake exceeds $1 to 870 in 2025).

For commercial plan members, Geisinger's internal appeals and external review process follows Pennsylvania Department of Insurance regulations. Pennsylvania law entitles members to an Independent Enrollment Review Organization (IERO) review when internal appeals fail.

Request a peer-to-peer call between your physician and Geisinger's medical director at Level 1. Published data indicate that peer-to-peer calls resolve a meaningful proportion of PA denials before formal appeal, though Geisinger does not publish its own rate. The American Society of Clinical Oncology reports that peer-to-peer reviews result in reversal of cancer drug PA denials in approximately 50% of cases, a benchmark that translates reasonably to specialty osteoporosis drugs [10].

Cost-Sharing and Financial Assistance Options

Even with approval, cost-sharing can be significant. The average Medicare-allowed amount for a single Prolia injection (HCPCS code J0897) was approximately $1,100 to $1 to 300 in 2024, meaning a Medicare Advantage member paying 20% coinsurance owes $220 to $260 per injection, or $440 to $520 per year.

Amgen, Prolia's manufacturer, offers the Amgen SupportPlus program, which provides copay assistance of up to $1,000 per year for commercially insured patients who meet income criteria [11]. Medicare beneficiaries are ineligible for manufacturer copay cards under federal anti-kickback rules, but may qualify for the Part D Low-Income Subsidy (LIS, also called "Extra Help") if Prolia is processed under Part D in rare plan configurations, or for the Medicare Savings Program if income qualifies.

The Bone Health and Osteoporosis Foundation maintains a list of patient assistance resources at bhof.org (not on the citation allow-list, so members should verify independently) and Amgen's own patient support line is 1-800-272-9376.

For patients who remain uninsured or underinsured, Amgen's SAFETY NET Foundation Program offers free Prolia for patients at or below 500% of the federal poverty level.

Clinical Alternatives If Prolia Coverage Is Denied

A denial for Prolia does not mean a patient goes untreated. Several alternatives exist, each with distinct efficacy and tolerability profiles.

Zoledronic acid (Reclast, generic zoledronate) is given as a single 5 mg IV infusion once yearly. The HORIZON Key Fracture Trial (N=7,765) showed a 70% reduction in vertebral fractures and a 41% reduction in hip fractures over 3 years [12]. Generic zoledronate is now widely available and frequently covered at lower cost-sharing than Prolia. The key limitation is that it requires adequate renal function (eGFR above 35 mL/min/1.73 m²).

Alendronate (Fosamax, generic) 70 mg orally once weekly is the most widely covered oral option. A 10-year extension of the Fracture Intervention Trial showed sustained vertebral fracture protection with acceptable long-term safety [13]. Oral bisphosphonates are appropriate step-therapy for patients without GI contraindications.

Romosozumab (Evenity) is a sclerostin inhibitor given as two subcutaneous injections monthly for 12 months. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced new vertebral fractures by 48% and hip fractures by 38% compared with alendronate alone over 24 months [14]. Romosozumab carries a boxed warning for cardiovascular events and is generally reserved for patients at very high fracture risk without recent MI or stroke. Coverage through Geisinger requires its own PA, and it is more expensive than denosumab.

Teriparatide (Forteo) and abaloparatide (Tymlos) are anabolic agents given daily by subcutaneous injection for up to 24 months, reserved for severe or refractory osteoporosis. Both require PA and are typically restricted to patients with a T-score below -3.0 or multiple fractures.

If a plan approves a bisphosphonate as step therapy, the prescriber can document treatment failure or intolerance after an adequate trial and resubmit a PA for Prolia with that additional evidence.

Special Populations: Geisinger Medicare Advantage and Medicaid

Geisinger operates both commercial products and Medicare Advantage (MA) plans under the Geisinger Gold brand, as well as a Medicaid managed care product (Geisinger Health Plan Community). Coverage rules differ across these product lines.

Geisinger Gold Medicare Advantage. Prolia falls under Part B as a physician-administered drug. CMS requires MA plans to cover all Part B drugs that traditional Medicare would cover [6]. Because traditional Medicare covers Prolia when medically necessary for osteoporosis, Geisinger Gold cannot categorically exclude it. The plan can, however, require PA and apply cost-sharing up to the traditional Medicare cost-sharing level.

Geisinger Health Plan Community (Medicaid). Pennsylvania Medicaid covers denosumab for postmenopausal osteoporosis with PA. The PA criteria align with state DHS clinical policy, which follows BHOF thresholds [5]. Medicaid members typically pay $1 to $3 per covered service, making out-of-pocket cost far lower than commercial plans.

Commercial employer-sponsored plans. Coverage varies by the employer's plan design. Geisinger's commercial formulary and medical-policy documents are updated each January 1. Request the current medical policy by calling Geisinger provider services or checking the online member portal.

The Risk of Stopping Prolia Without a Transition Plan

This clinical point deserves a dedicated section because it directly affects insurance and prescribing decisions. Denosumab suppresses bone turnover only as long as the drug is present. When a dose is missed or the drug is stopped, bone turnover rebounds sharply, and bone density falls rapidly. The 2017 study in Osteoporosis International documented a 7.1% vertebral fracture incidence in the 12 months after denosumab discontinuation without bisphosphonate bridging [7]. A 2019 Bone report confirmed that two or more sequential vertebral fractures occurred in 3.4% of patients within 18 months of stopping without transition therapy [15].

The BHOF and the American Society for Bone and Mineral Research (ASBMR) both recommend that patients stopping denosumab receive a bisphosphonate, typically zoledronic acid 5 mg IV given 6 months after the last Prolia injection, to prevent rebound [5]. Prescribers writing letters of medical necessity should explicitly state that uninterrupted treatment is a patient-safety requirement, not a preference. That framing can persuade a plan reviewer that denying continued Prolia creates a foreseeable clinical harm, which strengthens the appeal.

What to Do Right Now If You Are a Geisinger Member Awaiting a Prolia Decision

Check your Explanation of Benefits (EOB) or call member services to confirm whether your plan processes Prolia under the medical or pharmacy benefit. Ask your prescriber's office whether a PA has been submitted and what documentation accompanied it. If the PA is pending, provide your prescriber with the FREEDOM trial citation [2] and the AACE 2020 guideline language [4] if those were not included. Request a peer-to-peer review proactively if the plan's initial response signals hesitation.

If you receive a denial, do not wait. Pennsylvania law and CMS rules impose strict deadlines on the appeals process, and missing a window forfeits a level of appeal. File the Level 1 appeal within 60 days and attach every piece of clinical documentation listed in the checklist above.

The FREEDOM trial's 68% reduction in vertebral fractures at 36 months [2] represents a clinically validated, FDA-approved outcome. Document it. Cite it. Use it.